Document:USA 21 CFR Part 320 09-Apr-2025: Difference between revisions
From GxPlex
Gxplex admin (talk | contribs) m 1 revision imported |
gxplex>GxPlexBot Import from GxPlex Excel |
||
| Line 40: | Line 40: | ||
<noinclude> | <noinclude> | ||
== References == | == References == | ||
{| class="wikitable | {| class="wikitable" | ||
! Reference !! Scope !! Document part !! Language !! Preview | ! Reference !! Scope !! Document part !! Language !! Preview | ||
|- | |- | ||
Revision as of 15:06, 29 June 2026
| Document information | |
|---|---|
| Reference | USA 21 CFR Part 320 09-Apr-2025 |
| Validity area | USA |
| Scope(s) | HM |
| Document name | 21 CFR Part 320 |
| Version / Revision | 09-Apr-2025 |
| Status | Current |
| Document type | Legal act |
| Language(s) | EN |
| Description | Title 21 —Food and Drugs
Chapter I —Food and Drug Administration, Department of Health and Human Services Subchapter D—Drugs for Human Use Part 320 Bioavailability and Bioequivalence Requirements https://www.ecfr.gov/current/title-21 |
| Official source | Official link |
| Restricted access | No |
| Submitted by | Florian Adragna |
| Contributors | |
References
| Reference | Scope | Document part | Language | Preview |
|---|---|---|---|---|
| Reference:USA 21 CFR Part 320 09-Apr-2025 § 320.22 | HM | § 320.22 | EN | § 320.22 Criteria for waiver of evidence of in vivo bioavailability or bioequivalence. […] |
